WS #10669
Merck KGaA to acquire Bio-Techne at $73/share in cash, EV $11.3B; deal expected to be immediately accretive to sales and EBITDA.
Merck KGaA acquires Bio-Techne for $11.3B
Merck KGaA to acquire Bio-Techne at $73/share in cash, EV $11.3B; deal expected to be immediately accretive to sales and EBITDA.